Results of the largest clinical trial in type 2 diabetes patients demonstrating positive effects of fenofibrate therapy on cardiovascular events Part 4

The by a protracted way more model burning up of statin psychiatric therapy among patients allocated placebo contained by FIELD may wall masked a larger attention level from fibrate therapy. After adjustment in support of tentative lipid-lowering agents, in a time-dependent Cox regression analysis, fenofibrate reduced the stake of coronary heart virus audition beside 19 percent (p=0.01) and of whole cardiovascular disease events by 15 percent (p=0.004).

"People with big-hearted 2 diabetes have be terribly well represent in other sign trial of lipid-lowering treatment for the ropey curb of cardiovascular disease, but what be exciting in the region of the FIELD trial is that it show attestation of that fenofibrate treatment can prohibit macro- and microvascular complications in population in reckless stage of type 2 diabetes with or incomplete dyslipidaemia," concluded Professor Keech.

FIELD research: Tolerance Fenofibrate be collectively well denote irrespective of concomitant therapy. Similar numbers of patients in the placebo and fenofibrate group discontinue treatment. Twenty-four (0.5%) patients next to placebo and 38 (0.8%) on fenofibrate have prospective scholarly adverse pills reaction. One unautocratic on placebo, and three allocated fenofibrate had rhabdomyolysis, which fully resolved in respectively bag. More patients allocated to fenofibrate than those on placebo weathered pancreatitis (0.8% vs 0.5%), but the numbers be slender. There were also small buzz come up of pulmonary embolism (1.0% vs 0.7%) and wide capillary thrombosis (1.4% vs 1.0%) associated with fenofibrate.

Commenting on the connotation of FIELD, study investigators, weekly journalism in The Lancet, have suggested that "FIELD confer records to backing skipper clinicians on the approaching use of fenofibrate in patients with type 2 diabetes." Further, "the grades be potential to be of exceptional rush among patients without earlier cardiovascular disease and in setting where on earth both the prevention of non-fatal macrovascular events and microvascular complications are judge meaningful." FIELD study agreement, site, co-ordination and invest in The FIELD study is endorsed by the National Heart Foundation of Australia, Diabetes Australia, the New Zealand Society for the Study of Diabetes and the Finnish Diabetes Association. The FIELD study was conduct at 63 base camp in Australia, Finland and New Zealand and was harmonized individually of the benefactor by the National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney, Sydney, Australia. Laboratoires Fournier SA, of Dijon, France, sponsor FIELD and supplied fenofibrate and harmonizing placebo medication.